Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Comparison of gefitinib, erlotinib and afatinib in non-small cell lungcancer: A meta-analysis. Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non-small cell lungcancer (NSCLC) with proven efficacy. We undertook a systematic review and meta-analysis to synthesize existing studies with direct comparisons of EGFR TKIs in NSCLC in terms of both efficacy and safety. Eight randomized trials and 82 (...) cohort studies with a total of 17,621 patients were included for analysis. Gefitinib and erlotinib demonstrated comparable effects on progression-free survival (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.95 to 1.04), overall survival (HR, 0.99; 95% CI, 0.93 to 1.06), overall response rate (risk ratio [RR], 1.05; 95% CI, 1.00 to 1.11), and disease control rate (RR, 0.98; 95% CI, 0.96 to 1.01), which did not vary considerably with EGFR mutation status, ethnicity, line of treatment
Optimization of Chest Tube Management to Expedite Rehabilitation of LungCancer Patients After Video-Assisted Thoracic Surgery: A Meta-Analysis and Systematic Review. The aim of this meta-analysis and systematic review of published evidence was to optimize chest tube management for fast-track rehabilitation of lungcancer patients after video-assisted thoracic surgery (VATS).The PubMed, Web of Science, and EMBASE databases were searched to identify all studies that addressed the issue of chest (...) tube management after VATS for lungcancer. Finally, 35 articles were included for analysis, i.e., 29 randomized controlled trials and 6 clinical trials.After synthesis of the published evidence, the following protocol for chest tube drainage was formulated: (1) after VATS lung wedge resection, chest tube drainage can be omitted in selected cases; (2) normally, one 28Fr chest tube (or 19Fr Blake drain) is placed; (3) the use of a digital monitoring system is recommended; (4) in case of increasing
Snail acetylation by histone acetyltransferase p300 in lungcancer Epithelial to mesenchymal transition (EMT) is a complex and dynamic molecular event in lungcancer metastasis that has not yet been thoroughly investigated. EMT transcriptional factors, such as Snail, play a central role in regulation of the EMT process. In this study, we sought to identify an association between p300 and Snail in lungcancer, as well as the engagement of p300 in Snail acetylation.We transfected p300 small (...) interfering RNA into lungcancer cells to detect Snail and E-cadherin expression levels by real time-PCR. Immunoprecipitation assay was conducted to determine Snail acetylation in vivo. Bacteria-expressed Snail was purified to analyze Snail acetylation in vitro. We further mutated lysine 187 for identifying acetylated residue in Snail.Snail transcription in lungcancer cells was repressed by p300 knockdown. E-cadherin expression was increased by transfection of p300 small interfering RNA in a dose
Autoimmune paraneoplastic syndromes associated to lungcancer: A systematic review of the literature. The development of new immune treatment in oncology and particularly for lungcancer may induce new complications, particularly activation or reactivation of auto-immune diseases. In this context, a systematic review on the auto-immune paraneoplastic syndromes associated with lungcancer appears useful. This article is the first of a series of five and deals with the methodology applied
Autoimmune paraneoplastic syndromes associated to lungcancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. The development of new immune treatment in oncology and particularly for lungcancer may induce new complications, particularly activation or reactivation of auto-immune diseases. In this context, a systematic review on the auto-immune paraneoplastic syndromes that can complicate lungcancer appears useful
Autoimmune paraneoplastic syndromes associated to lungcancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes. The development of new immune treatment in oncology and particularly for lungcancer may induce new complications, particularly activation or reactivation of auto-immune diseases. In this context, a systematic review on the auto-immune paraneoplastic syndromes associated with lungcancer appears useful. This article is the second
Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lungcancer patients: A systematic review and meta-analysis. PET/CT is a proposed management to improve the accuracy of high dose radiochemotherapy in lungcancer patients. This systematic review was performed to investigate the possible impact on clinical outcome and to quantify the effect on patient selection and target definition.Systematic (...) literature searches were conducted, eligible full-text articles were assessed for quality and data were extracted.Thirty-five cross-sectional studies and one observational study fulfilled the inclusion criteria. No randomized trials or data with regard to clinical endpoints were found. The summary estimates of a change in target definition were 36% in patients with a former staging PET, and 43% and 26% in patients without a staging PET, for non small- and small cell lungcancer respectively
Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lungcancer 29063051 2018 11 13 2095-882X 3 1 2017 Mar 25 Chronic diseases and translational medicine Chronic Dis Transl Med Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lungcancer. 1-7 10.1016/j.cdtm.2017.02.009 Lu Ying-Qiang YQ Department of Clinical Medicine, The First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210029, China. Lu (...) Kai-Hua KH Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China. eng Editorial 2017 03 11 China Chronic Dis Transl Med 101679934 2095-882X Diagnosis Drug resistance Next-generation sequencing Non-small-cell lungcancer Therapy 2016 10 20 2017 10 25 6 0 2017 10 25 6 0 2017 10 25 6 1 epublish 29063051 10.1016/j.cdtm.2017.02.009 S2095-882X(16)30093-7 PMC5627693 Int J Cancer. 2015 Mar 1;136(5):E359-86 25220842 Lancet Oncol. 2012 Oct;13(10
of audiovisual biofeedback breath-hold (AVBH) on interfraction lungtumor position reproducibility and volume consistency for respiratory-gated lungcancer radiation therapy.Lung tumor position and volume were investigated in 9 patients with lungcancer who underwent a breath-hold training session with AVBH before 2 magnetic resonance imaging (MRI) sessions. During the first MRI session (before treatment), inhalation and exhalation breath-hold 3-dimensional MRI scans with conventional breath-hold (CBH) using (...) Audiovisual biofeedback guided breath-hold improves lungtumor position reproducibility and volume consistency Respiratory variation can increase the variability of tumor position and volume, accounting for larger treatment margins and longer treatment times. Audiovisual biofeedback as a breath-hold technique could be used to improve the reproducibility of lungtumor positions at inhalation and exhalation for the radiation therapy of mobile lungtumors. This study aimed to assess the impact
Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lungcancer: a meta-analysis of randomized controlled clinical trials. There is debate surrounding which treatment is superior in overall survival (OS) rates in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lungcancer (NSCLC); first-line tyrosine kinase inhibitor (TKI) followed by second-line platinum-based doublet chemotherapy (PCT (...) ), or the reverse sequence. Cross treatment of first- and second-line TKI and PCT makes it difficult to deduce which sequence (TKI-PCT or PCT-TKI) is better for OS. Using the keywords "lungcancer" and "EGFR" we identified clinical trials within the PubMed database which were published between January 2006 and November 2016. Basic characteristics and OS with hazard ratio and 95% confidence intervals were searched and analyzed. In total, 457 articles were reviewed and nine clinical trials with 1,876 patients
Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lungcancer? A meta-analysis. We performed a meta-analysis to compare overall survival (OS) outcomes in patients with synchronous oligometastatic non-small cell lungcancer (NSCLC) who underwent aggressive thoracic therapy (ATT) with those who did not.A systematic review of controlled trials of ATT on survival in synchronous oligometastatic NSCLC was conducted. Hazard ratio (HR (...) ) for the main endpoint OS was pooled using a fixed-effects model. Subgroup analysis was performed in patients with single organ metastases, or with different numbers of brain metastases, or with different stages of thoracic disease. Pooled survival curves of OS were constructed.Seven eligible retrospective observational cohort studies were identified including 668 synchronous oligometastatic NSCLC patients, of whom 227 (34.0%) received ATT. For patients with synchronous oligometastatic NSCLC, ATT
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line nonsquamous non-small cell lungcancer studies. This meta-analysis compared safety profiles (selected drug-related treatment-emergent adverse events [TEAEs]) of first-line pemetrexed plus carboplatin (PCb) area under the concentration-time curve 5 mg/min•mL (PCb5) or 6 mg/min•mL (PCb6), two widely used regimens in clinical practice for advanced non-squamous non-small cell lung cancer.All patients received
Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lungcancer: a systematic review and meta-analysis. This meta-analysis evaluated whether pretherapy serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) are predictive of response to therapy in non-small cell lungcancer (NSCLC) and whether changes in these markers during vs pretherapy are indicative of response.Original peer-reviewed studies enrolling (...) adults with untreated advanced NSCLC were identified using PubMed. Two reviewers independently extracted data from eligible studies and assessed study heterogeneity and the risk of study bias.Fourteen studies were eligible; 11 had objective response as an end point and three evaluated clinical benefit (i.e., response and stable disease). Study bias was relatively low. Both markers showed comparable modest predictive value across studies, with baseline CYFRA 21-1 numerically better in predicting
Epidemiological evidence on environmental tobacco smoke and cancers other than lung or breast. We reviewed 87 epidemiological studies relating environmental tobacco smoke (ETS) exposure to risk of cancer other than lung or breast in never smoking adults. This updates a 2002 review which also considered breast cancer. Meta-analysis showed no significant relationship with ETS for nasopharynx cancer, head and neck cancer, various digestive cancers (stomach, rectum, colorectal, liver, pancreas (...) ), or cancers of endometrium, ovary, bladder and brain. For some cancers (including oesophagus, colon, gall bladder and lymphoma) more limited data did not suggest a relationship. An increased cervix cancer risk (RR 1.58, 95%CI 1.29-1.93, n = 17 independent estimates), reducing to 1.29 (95%CI 1.01-1.65) after restriction to five estimates adjusting for HPV infection or sexual activity suggests a causal relationship, as do associations with nasosinus cancer observed in 2002 (no new studies since), and less
to investigate a total of 234 pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.META-GSA reveals the systemic lupus erythematosus KEGG pathway hsa05322, driven by the gene region 6p21-22, as also implicated in lungcancer (p = 0.0306). This gene region is known to be associated with squamous cell lungcarcinoma. The most important genes driving the significance of this pathway belong to the genomic areas HIST1-H4L, -1BN, -2BN, -H2AK, -H4K and C2/C4A/C4B. Within these areas (...) Gene-set meta-analysis of lungcancer identifies pathway related to systemic lupus erythematosus. Gene-set analysis (GSA) is an approach using the results of single-marker genome-wide association studies when investigating pathways as a whole with respect to the genetic basis of a disease.We performed a meta-analysis of seven GSAs for lungcancer, applying the method META-GSA. Overall, the information taken from 11,365 cases and 22,505 controls from within the TRICL/ILCCO consortia was used
CHRNA5 rs16969968 Polymorphism Association with Risk of LungCancer--Evidence from 17,962 LungCancer Cases and 77,216 Control Subjects. Genetic studies have shown a possible relationship between the rs16969968 polymorphism in CHRNA5 and the risk of lungcancer. However, the results have been conflicting. Thus we rigorously conducted a meta-analysis to clarify any association.A total of 10 case-control studies involving 17,962 lungcancer cases and 77,216 control subjects were analysed. Odds (...) ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of the association.We found the CHRNA5 rs16969968 polymorphism to be associated with the risk of lungcancer (AA vs GG: OR=1.60, 95%CI=1.51-1.71). On stratified analysis by smoking status, a statistically significant increased risk was observed in the smoking group (AA vs GG: OR=1.80, 95%CI=1.61-2.01). However, this polymorphism was not associated with lungcancer risk in Asians (AA vs GG: OR=0.95, 95%CI=0.35-2.59
Meta-analysis of the association between the rs8034191 polymorphism in AGPHD1 and lungcancer risk. Possible associations between the single nucleotide polymorphism (SNP) rs8034191 in the aminoglycosidephosphotransferase domain containing 1 (AGPHD1) gene and lungcancer risk have been studied by many researchers but the results have been contradictory.A computerized search for publications on rs8034191 and lungcancer risk was performed. Odds ratios (ORs) with 95% confidence intervals (CIs (...) ) were calculated to assess the association between rs8034191 and lungcancer risk with 13 selected case-control studies. Sensitivity analysis, test of heterogeneity, cumulative meta-analysis, and assessment of bias were also performed.A significant association between rs8034191 and lungcancer susceptibility was found using the dominant genetic model (OR=1.344, 95% CI: 1.285-1.406), the additive genetic model (OR=1.613, 95% CI: 1.503-1.730), and the recessive genetic model (OR=1.408, 95% CI: 1.319
Folate pathway gene MTHFR C677T polymorphism and risk of lungcancer in Asian populations. Previous studies concerning the association between the 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism with lungcancer in Asian populations have provided inconclusive findings.A meta-analysis was performed to investigate a more reliable association between MTHFR C677T polymorphism and lungcancer in Asians.A comprehensive search was conducted to identify all case-control studies (...) of MTHFR polymorphisms and lungcancer in Asia, using odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of any association.Meta-analysis results suggested that the MTHFR C677T polymorphism contributed to an increased lungcancer risk in Asian populations (for T vs C: OR=1.11, 95%CI=1.0-1.23; for CT vs CC: OR= 1.1, 95%CI= 0.95-1.2 ; for TT+CT vs CC: OR=1.13, 95%CI=1.0-1.30; for TT vs CC: OR=1.25, 95%CI=1.01-1.30; for TT vs CT+CC: OR=1.16, 95%CI=1.0-1.36).MTHFR C677T
Emerging challenges of advanced squamous cell lungcancer Squamous cell lungcancer (SQCLC) is an aggressive type of lungcancer and most are diagnosed at advanced stage. Patients with advanced SQCLC tend to be older, current or former smoker, with central type tumour located near large blood vessels and seldom with druggable genetic alternations. Consequently, progress of targeted therapy and antivascular agents available in lungadenocarcinoma could not be duplicated in this subset
Successful osimertinib treatment for leptomeningeal carcinomatosis from lungadenocarcinoma with the T790M mutation of EGFR Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lungcancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficacy against leptomeningeal carcinomatosis (LMC) derived from NSCLC resistant